MedTrace Logo

A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms

NCT06755671 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 4500

Last updated 2025-05-14

No results posted yet for this study

Summary

The goal of this observational study is to evaluate if Danning Tablets are effective in alleviating dyspepsia in patients with any of the following digestive symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation.

The main questions it aims to answer are:

How effective are Danning Tablets for patients with indigestion symptoms? What are the impact factors (e.g. severity of conditions, demographic features, dose and length of treatment etc.) of the efficacy of Danning Tablets for indigestion patients?

Participants already taking Danning Tablets as part of their regular medical care for indigestion will take questionnaires by the end of two weeks and four weeks respectively from the start of their treatment.

Conditions

  • Indigestion
  • Dyspepsia
  • Bloating
  • Loss of Appetite
  • Reflux Acid
  • Constipation
  • Upper Abdominal Pain
  • Functional Dyspepsia

Interventions

DRUG

Danning Tablet

Danning Tablet is the only exposure in this observational study.

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER

  • Shanghai Hutchison Pharmaceuticals Limited

    lead INDUSTRY

Principal Investigators

  • Jianting CAI, Doctor of Medicine · Second Affiliated Hospital, School of Medicine, Zhejiang University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-30
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06755671 on ClinicalTrials.gov